Settings Associated with Optimal Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes
Authors' conclusion
These results provide actionable guidance for clinicians to optimize outcomes for people with T1D using the Omnipod 5 System.
Study context
- Population
- Omnipod 5 users aged ≥2 years with T1D in the United States and Europe with sufficient CGM data, January 1 to March 31, 2025analysed
- Participants
- 176,405 participants
- Exposure
- Users with optimized device settings and expected system use vs users overall
- Outcome
- Achieving >70% TIR (70-180 mg/dL [3.9-10.0 mmol/L])
Methodological detailsreal-world data, United States and Europe
- Real-world data
- United States and Europe
Main finding
As reported in the abstract
Predictors of achieving >70% TIR
- Higher number of user-initiated boluses/day, greater time in Automated Mode, lower glucose targets, and more aggressive correction factor (CF) and I:C ratio predicted >70% time in range (TIR)
- all P < 0.001
Observational data: associations, not effects.
Further findings
Median
| Outcome | Optimized settings | Users overall |
|---|---|---|
| Median TIR, adult users | 77% | 66% |
| Median TIR, pediatric users | 78% | 62% |
- Median TIR, adult users — Adult users using optimized settings with expected system use
- 7.9%
- Median TIR, pediatric users — Pediatric users using optimized settings with expected system use
- 1.4%
Consistency
- Findings were consistent across geographic regions and prior insulin regimen
Safety
- Time spent in hypoglycemia remained low across age groups
Original publication
Settings Associated with Optimal Glycemic Outcomes with the Omnipod® 5 Automated Insulin Delivery System: Evidence from Real-World Users with Type 1 Diabetes. Diabetes Technol Ther. Published 24 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →